Self-Assembled “Dock and Lock” System for Linking Payloads to Targeting Proteins
- 25 May 2006
- journal article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 17 (4) , 912-919
- https://doi.org/10.1021/bc060037u
Abstract
Random conjugation of therapeutic or diagnostic payloads to targeting proteins generates functionally heterogeneous products. Conjugation of payloads to an adapter that binds to a peptide tag engineered into a targeting protein provides an alternative strategy. To progress into clinical development, an adapter/docking tag system should include humanized components and be stable in circulation. We describe here an adapter/docking tag system based on mutated fragments of human RNase I that spontaneously bind to each other and form a conjugate with a disulfide bond between complimentary cysteine residues. This self-assembled "dock and lock" system utilizes the previously described fusion C-tag, a 1-15 aa fragment of human RNase I with the R4C amino acid substitution, and a newly engineered adapter protein (Ad-C), a 21-127-aa fragment of human RNase I with the V118C substitution. Two vastly different C-tagged recombinant proteins, human vascular endothelial growth factor (VEGF) and a 254-aa long N-terminal fragment of anthrax lethal factor (LFn), retain functional activities after spontaneous conjugation of Ad-C to N-terminal or C-terminal C-tag, respectively. Ad-C modified with pegylated phospolipid and inserted into the lipid membrane of drug-loaded liposomes (Doxil) retained the ability to conjugate C-tagged proteins, yielding targeted liposomes decorated with functionally active proteins. To further optimize the system, we engineered an adapter with an additional cysteine residue at position 88 for site-specific modification, conjugated it to C-tagged VEGF, and labeled with a near-infrared fluorescent dye Cy5.5, yielding a unique functionally active probe for in vivo molecular imaging. We expect that this self-assembled "dock and lock" system will provide new opportunities for using functionally active proteins for biomedical purposes.Keywords
This publication has 12 references indexed in Scilit:
- Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody DisulfidesBioconjugate Chemistry, 2005
- Nanomedicine: current status and future prospectsThe FASEB Journal, 2004
- Avidin/biotin-liposome system injected in the pleural space for drug delivery to mediastinal lymph nodesJournal of Pharmaceutical Sciences, 2004
- Assembly of targeting complexes driven by a single-chain antibodyJournal of Immunological Methods, 2004
- Production of Soluble ScFvs with C-Terminal-Free Thiol for Site-Specific Conjugation or Stable Dimeric ScFvs on DemandBioconjugate Chemistry, 2003
- Humanized docking system for assembly of targeting drug delivery complexesJournal of Controlled Release, 2003
- Reduction of Kidney Uptake in Radiometal Labeled Peptide Linkers Conjugated to Recombinant Antibody Fragments. Site-Specific Conjugation of DOTA-Peptides to a Cys-DiabodyBioconjugate Chemistry, 2002
- Targeting Endothelial Cells Overexpressing VEGFR-2: Selective Toxicity of Shiga-like Toxin−VEGF Fusion ProteinsBioconjugate Chemistry, 2001
- Functionally Active VEGF Fusion ProteinsProtein Expression and Purification, 2001
- Bispecific and bifunctional single chain recombinant antibodiesBiomolecular Engineering, 2001